29 Aug 2017WALTHAM, Mass., /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has completed its acquisition of Patheon N.V. (NYSE: PTHN), a leading contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology sectors, for approximately $7.2 billion. Today's close follows the expiration of Thermo Fisher's initial tender offer for Patheon at $35.00 per share in cash."We're pleased to complete ourmore...
22 Aug 2017Patheon Announces Intent to Voluntarily Delist from the NYSE Subject to and Conditioned upon the Initial Expiration of the Tender Offer and Acquisition of Shares by Thermo FisherDURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V., a public limited liability company (naamloze vennootschap) organized under the laws of The Netherlands (NYSE: PTHN) (“Patheon”), today announced that it has submitted written notice to the New York Stock Exchange (the “NYSE”) of its intention to voluntarily delist its ordinary shares, par value €0.01 per share (the “Shares”), from the NYSE. The voluntary delisting is subject to and conditioned upon (1) the initial expiration of themore...
08 Jun 2017
DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017. Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $more...
- 2Q 2017 revenue of $483 million
- Net income from continuing operations of $28 million
- Net income from continuing operations per diluted share of $0.19
- 2Q 2017 Adjusted EBITDA of $94 million
- Adjusted net income from continuing operations of $29 million
- Adjusted net income from continuing operations per diluted share of $0.20